ストックスクリーナーアプリを入手
53.27
0.74%
0.39
アフターアワーズ：
53.27
Sanofi Adr (SNY) 最新ニュース
Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes
Here’s Why Mastercard Incorporated (NYSE: MA) Is An Attractive Investment Right Now - Stocks Register
Weekly Upgrades and Downgrades - InvestorPlace
16 New 4-Star Stocks - Morningstar
Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research - TopNews India
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading - MSN
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat - Investor's Business Daily
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup - Investing.com
Sanofi, HCA, Colgate-Palmolive lead Friday's earnings lineup By Investing.com - Investing.com UK
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI - GlobeNewswire Inc.
Sanofi Deal Jitters Imperil Stock’s Big Rebound - MSN
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale - Zacks Investment Research
Proactive news headlines: Ananda, Helix Exploration, Deltic, Light Science Technologies and more - Proactive Investors UK
French govt set to take stake in Sanofi unit after PE sale - Proactive Investors Australia
Sanofi Negotiating Exclusively With CD&R For Opella 50% Stake Sale - Barchart
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Sanofi ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Ratios Reveal: Breaking Down Sanofi ADR (SNY)’s Financial Health - The Dwinnex
EXK (Endeavour Silver Corp.) may reap gains as insiders became active recently - Knox Daily
Checking in on Clear Channel Outdoor Holdings Inc. (CCO) after recent insiders movement - Knox Daily
Investing in Sanofi ADR (SNY): What You Must Know - Knox Daily
Investing in Replimune Group Inc (REPL) Is Getting More Attractive - Knox Daily
An Analysis of KE Holdings Inc ADR (BEKE)’s Potential Price Growth - Knox Daily
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
OTC Drug and Dietary Supplement Market Opportunities and Strategies to 2033 - GlobeNewswire Inc.
The SNY Stock Puzzle: Unraveling Sanofi ADR’s Fluctuating Performance - The InvestChronicle
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent - Investor's Business Daily
Buy These 5 Big Drug Stocks To Boost Your Portfolio's Health - Barchart
Company’s Banking Stock: Dissecting a 21.83% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Sanofi Stock Up Almost 23% In 3 Months: Buy, Sell Or Hold? - Barchart
Ratio Analysis: Unpacking Sanofi ADR (SNY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Market Analysts see Sanofi ADR [SNY] gaining to $60. Time to buy? - The DBT News
India Insulin Delivery Devices Market Size & Outlook, 2030 - Grand View Research
Sanofi ADR Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
0.78%
0.74%
大文字化:
|
ボリューム (24 時間):